BEIJING, Feb. 20, 2009 (GLOBE NEWSWIRE) -- Kiwa Bio-Tech Products Group Corporation (OTCBB:KWBT) announced that the Board of Directors appointed Mr. Steven Ning MA as CFO and COO.
Mr. Ma's most recent position was as Managing Director of SAS Conserve de Provence in Camaret sur Aguy, France. There he was in charge of overall operation of a French subsidiary for Chalkis Group with annual sales of 70 million Euros and over 250 employees. His expertise includes debt and asset repackaging, trademark and goodwill valuation, fund raising proposal for strategic investors, corporate credit crisis management, cash flow, and inventory management. Other recent positions include Senior Managing Partner of HJV (Hejun) Consulting (Ltd) in Shanghai, China and Ulaanbaatar, Mongolia. He also served as CFO/COO of Summiteam Solutions (Ltd.) Shanghai, China.
Mr. Ma's has worked for companies in industries related to Kiwa's business including Pioneer Hi-Bred Asia-Pacific, Nanjing Organon Pharm'cal Co. (Ltd.) and Chinese Academy of Agric'l Sciences. His international experience includes work in the Netherlands.
His education credentials include a Bachelor in Sciences /Chemistry from Nanjing University; a Master in Economics /Finance from the Graduate School, Chinese Academy of Sciences. He holds a certificate of Development Studies from International Center for Development Studies Wageningen, Netherlands and has completed course work in Financial Economics also at Wageningen University.
ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION
The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (www.sec.gov) or visit the Company's website at www.kiwabiotech.com.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.